No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection By Ogkologos - June 22, 2026 151 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR Simple Hysterectomy Noninferior to Radical Hysterectomy with Respect to Pelvic Recurrence... February 29, 2024 Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:... February 8, 2021 Program Connects Adolescents and Young Adults to Quality Cancer Care October 24, 2024 FDA Approves Acalabrutinib with Venetoclax for CLL or SLL March 4, 2026 Load more HOT NEWS Building on Success, Maximizing Opportunities: NCI’s Annual Plan & Budget Proposal Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL Death Rates from Lung Cancer will Fall Overall in the EU...
